Leerink Partnrs Has Weak Estimate for CVS Health Q2 Earnings

CVS Health Co. (NYSE:CVS) – Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings per share (EPS) estimates for shares of CVS Health in a research report issued on Thursday, May 1st. Leerink Partnrs analyst M. Cherny now expects that the pharmacy operator will post earnings of $1.45 per share for the quarter, down from their prior forecast of $1.54. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for CVS Health’s current full-year earnings is $5.89 per share. Leerink Partnrs also issued estimates for CVS Health’s Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $6.16 EPS, FY2026 earnings at $7.17 EPS, FY2027 earnings at $8.29 EPS and FY2028 earnings at $9.39 EPS.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion during the quarter, compared to analysts’ expectations of $93.07 billion. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 EPS.

CVS has been the topic of a number of other reports. Wells Fargo & Company reiterated an “overweight” rating and issued a $84.00 price objective (up from $76.00) on shares of CVS Health in a research report on Tuesday. Barclays raised their target price on shares of CVS Health from $73.00 to $82.00 and gave the company an “overweight” rating in a research note on Friday, May 2nd. UBS Group upped their price target on shares of CVS Health from $67.00 to $71.00 and gave the stock a “neutral” rating in a research note on Friday, May 2nd. Wolfe Research boosted their price target on CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Argus set a $77.00 target price on CVS Health in a research report on Tuesday, February 18th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $74.81.

CVS Health Stock Down 1.2 %

Shares of CVS Health stock opened at $66.32 on Monday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company’s 50 day moving average price is $66.82 and its 200-day moving average price is $58.85. The stock has a market capitalization of $83.61 billion, a price-to-earnings ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.60. CVS Health has a 52-week low of $43.56 and a 52-week high of $72.51.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.01%. CVS Health’s dividend payout ratio is currently 63.48%.

Insider Transactions at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael F. Mahoney bought 30,000 shares of CVS Health stock in a transaction on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.22% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Ridgewood Investments LLC lifted its holdings in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 450 shares during the last quarter. Stonebridge Financial Group LLC purchased a new stake in CVS Health in the fourth quarter valued at about $28,000. GW&K Investment Management LLC boosted its holdings in CVS Health by 39.4% in the first quarter. GW&K Investment Management LLC now owns 637 shares of the pharmacy operator’s stock worth $43,000 after acquiring an additional 180 shares in the last quarter. Hopwood Financial Services Inc. purchased a new stake in shares of CVS Health during the fourth quarter worth about $29,000. Finally, McIlrath & Eck LLC increased its holdings in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock valued at $32,000 after acquiring an additional 174 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.